Tirzepatide: what the definition actually tells you about how it works

What does 'dual GIP and GLP-1 receptor agonist' actually mean?

The phrase sounds technical, but it describes something fairly logical once you unpack it. Your gut produces two hormones (GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1)) when you eat. Together they signal fullness to the brain, help regulate blood sugar and slow the rate at which food leaves your stomach. Tirzepatide is a synthetic molecule engineered to activate the receptors for both of those hormones at the same time.

Earlier medicines in this class, including semaglutide, target GLP-1 alone. Tirzepatide's dual action is what distinguishes it pharmacologically, and it is why tirzepatide sits in its own category rather than being simply a stronger version of existing treatments. The NHS describes this mechanism clearly on its tirzepatide medicines page, worth reading if you want the patient-level explanation from a source you can trust.

A common misconception is that tirzepatide works by "burning fat" directly. It does not. What it does is reduce how hungry you feel and how quickly your stomach empties, which makes eating less feel far more manageable than willpower alone tends to. The weight loss follows from that shift in appetite, alongside a reduced-calorie diet and increased activity.

How does tirzepatide's definition differ from drugs with similar names?

Patients searching this topic often land here after seeing several names that sound interchangeable: tirzepatide, semaglutide, Mounjaro, Wegovy, Ozempic. They are not the same thing. If you want a clear, thorough answer to what tirzepatide actually is as a molecule, that page breaks down the definition in full. Mounjaro is the brand name Eli Lilly markets it under in the UK. Semaglutide is a different molecule, used in Wegovy and Ozempic.

Ozempic deserves a specific note because it comes up often. It contains semaglutide, but it is licensed in the UK for type 2 diabetes management, not weight loss. Using a diabetes medicine off-label for weight loss is a separate clinical and ethical matter entirely, and it is not a route that a responsible prescriber would take when a medicine is specifically licensed for weight management. If you want to understand how tirzepatide's mechanism compares at a deeper level, that page goes further into the pharmacology.

One practical point: the INN 'tirzepatide' appears on your prescription regardless of which brand-name pen you receive. If your pharmacist or prescriber uses that word, they are referring to the active ingredient, not a different product.

Who is tirzepatide licensed for, and what does the evidence say about results?

The UK licence, granted by the MHRA, covers adults with a BMI of 30 or above, or a BMI of 27 or above when at least one weight-related condition is present, for example, high blood pressure, high cholesterol, prediabetes, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. A prescriber weighs all of this against your full health picture; the number on a BMI chart is a starting point, not a guarantee of treatment.

The evidence base behind the licence is substantial. The SURMOUNT-1 trial, published in the New England Journal of Medicine, followed adults with obesity over 72 weeks and found average weight reductions of around 20–21% at the 15 mg dose. NICE reviewed that evidence as part of its appraisal process and recommended tirzepatide for use in the UK. You can read about what realistic results look like for individual patients, because trial averages and personal outcomes are usefully distinct conversations.

For a clear sense of what private treatment involves in terms of cost, the background on UK Mounjaro pricing is worth a read before you start comparing options.

What else should you know before the word 'tirzepatide' appears on your prescription?

Side effects are mostly gastrointestinal: nausea, diarrhoea, constipation, indigestion and occasional vomiting are the most frequently reported, particularly in the first weeks or after a dose increase. They tend to settle as your body adjusts. Serious effects are less common but include symptoms of pancreatitis (severe, persistent stomach pain that may spread to the back) which require prompt medical attention. The NHS tirzepatide page lists the full side-effect profile in plain language.

There are also a few populations for whom tirzepatide is not recommended: people who are pregnant, breastfeeding or actively trying to conceive, and those under 18. A history of certain thyroid or pancreatic conditions also requires careful prescriber discussion before treatment begins.

If you want to explore whether tirzepatide might be clinically appropriate for you, our prescribers can review your situation properly. Start your free consultation and a GPhC-registered Independent Prescriber will look at your answers the same day, not software, a real clinician.